A detailed history of Ubs Asset Management Americas Inc transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 880,453 shares of BMRN stock, worth $57.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
880,453
Previous 1,013,040 13.09%
Holding current value
$57.8 Million
Previous $83.4 Million 25.8%
% of portfolio
0.02%
Previous 0.02%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$69.02 - $93.84 $9.15 Million - $12.4 Million
-132,587 Reduced 13.09%
880,453 $61.9 Million
Q2 2024

Aug 13, 2024

BUY
$74.43 - $92.22 $20 Million - $24.7 Million
268,239 Added 36.01%
1,013,040 $83.4 Million
Q1 2024

May 15, 2024

SELL
$83.81 - $99.0 $154,126 - $182,061
-1,839 Reduced 0.25%
744,801 $65.1 Million
Q4 2023

Feb 14, 2024

SELL
$76.22 - $98.51 $739,029 - $955,152
-9,696 Reduced 1.28%
746,640 $72 Million
Q3 2023

Nov 13, 2023

SELL
$85.07 - $94.48 $8.57 Million - $9.51 Million
-100,693 Reduced 11.75%
756,336 $66.9 Million
Q1 2023

May 15, 2023

SELL
$87.74 - $117.27 $13.7 Million - $18.4 Million
-156,532 Reduced 15.44%
857,029 $83.3 Million
Q4 2022

Feb 14, 2023

SELL
$80.93 - $108.63 $21.1 Million - $28.3 Million
-260,605 Reduced 20.45%
1,013,561 $105 Million
Q3 2022

Nov 14, 2022

SELL
$82.16 - $96.94 $23.7 Million - $27.9 Million
-288,199 Reduced 18.45%
1,274,166 $108 Million
Q2 2022

Aug 12, 2022

BUY
$71.48 - $86.85 $768,267 - $933,463
10,748 Added 0.69%
1,562,365 $129 Million
Q1 2022

May 16, 2022

BUY
$74.28 - $92.69 $31.2 Million - $38.9 Million
419,371 Added 37.04%
1,551,617 $120 Million
Q4 2021

Feb 14, 2022

BUY
$71.72 - $91.47 $3.24 Million - $4.13 Million
45,170 Added 4.16%
1,132,246 $100 Million
Q3 2021

Nov 15, 2021

SELL
$74.77 - $85.47 $71.4 Million - $81.6 Million
-954,407 Reduced 46.75%
1,087,076 $84 Million
Q2 2021

Aug 16, 2021

SELL
$75.51 - $84.79 $14.8 Million - $16.7 Million
-196,578 Reduced 8.78%
2,041,483 $170 Million
Q1 2021

May 14, 2021

SELL
$74.73 - $90.69 $16.8 Million - $20.3 Million
-224,204 Reduced 9.11%
2,238,061 $169 Million
Q4 2020

Mar 01, 2021

BUY
$72.61 - $90.2 $32.3 Million - $40.1 Million
444,701 Added 22.04%
2,462,265 $216 Million
Q3 2020

Nov 13, 2020

BUY
$71.87 - $131.03 $61 Million - $111 Million
848,740 Added 72.61%
2,017,564 $153 Million
Q2 2020

Aug 14, 2020

SELL
$79.55 - $124.22 $10.9 Million - $17.1 Million
-137,364 Reduced 10.52%
1,168,824 $144 Million
Q1 2020

May 15, 2020

SELL
$71.37 - $96.85 $2.92 Million - $3.97 Million
-40,972 Reduced 3.04%
1,306,188 $110 Million
Q4 2019

Feb 14, 2020

BUY
$64.27 - $86.37 $12.5 Million - $16.8 Million
194,514 Added 16.88%
1,347,160 $114 Million
Q3 2019

Nov 14, 2019

BUY
$67.4 - $85.11 $9.24 Million - $11.7 Million
137,044 Added 13.49%
1,152,646 $77.7 Million
Q2 2019

Aug 15, 2019

SELL
$80.35 - $93.9 $12.3 Million - $14.3 Million
-152,762 Reduced 13.07%
1,015,602 $0
Q1 2019

May 14, 2019

SELL
$84.2 - $98.62 $1.34 Million - $1.56 Million
-15,858 Reduced 1.34%
1,168,364 $0
Q4 2018

Feb 13, 2019

BUY
$80.14 - $106.07 $5.19 Million - $6.86 Million
64,718 Added 5.78%
1,184,222 $101 Million
Q3 2018

Nov 14, 2018

SELL
$93.92 - $105.72 $5.46 Million - $6.14 Million
-58,085 Reduced 4.93%
1,119,504 $0
Q2 2018

Aug 14, 2018

BUY
$76.01 - $99.03 $2.2 Million - $2.87 Million
28,971 Added 2.52%
1,177,589 $0
Q1 2018

May 14, 2018

BUY
$77.67 - $92.63 $798,136 - $951,865
10,276 Added 0.9%
1,148,618 $0
Q4 2017

Feb 09, 2018

BUY
$80.76 - $95.13 $6.43 Million - $7.57 Million
79,591 Added 7.52%
1,138,342 $0
Q3 2017

Nov 13, 2017

BUY
$80.6 - $94.95 $85.3 Million - $101 Million
1,058,751
1,058,751 $0

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.2B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.